Clinical Trial Update: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of MK-2206 in pediatric patients with recurrent or refractory solid tumors or leukemias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Chronic Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Status: COMPLETED